| Sohma Integrative Medicine | |
|
4195 N Viking Way Ste F Long Beach CA 90808-1470 | |
| (562) 420-2112 | |
| (562) 420-2110 |
| Full Name | Sohma Integrative Medicine |
|---|---|
| Speciality | General Practice |
| Location | 4195 N Viking Way Ste F, Long Beach, California |
| Authorized Official Name and Position | Michael A Woo-ming (OWNER) |
| Authorized Official Contact | 5624202112 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Sohma Integrative Medicine 4195 N Viking Way Ste F Long Beach CA 90808-1470 Ph: (562) 420-2112 | Sohma Integrative Medicine 4195 N Viking Way Ste F Long Beach CA 90808-1470 Ph: (562) 420-2112 |
| NPI Number | 1205475738 |
|---|---|
| Provider Enumeration Date | 01/01/2020 |
| Last Update Date | 05/02/2024 |
| Medicare PECOS PAC ID | 6103256110 |
|---|---|
| Medicare Enrollment ID | O20200415000417 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205475738 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| Provider Name | Michael Woo-ming |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558623371 PECOS PAC ID: 2062324726 Enrollment ID: I20041005000612 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Provider Name | Daniel C Hoover |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1639578859 PECOS PAC ID: 8527388248 Enrollment ID: I20150520002686 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Provider Name | Aja Castillo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205383064 PECOS PAC ID: 8820378607 Enrollment ID: I20161213002751 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Provider Name | Carolina Sciambia |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710425814 PECOS PAC ID: 8729322540 Enrollment ID: I20181205003098 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Provider Name | Kevin H Kim |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1861930646 PECOS PAC ID: 0345585907 Enrollment ID: I20181231000913 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Provider Name | Jayashriben Patel |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205384948 PECOS PAC ID: 2466731633 Enrollment ID: I20191016002513 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
| Provider Name | Lisa Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770116808 PECOS PAC ID: 0143641118 Enrollment ID: I20201124002917 |
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
News Archive
Bristol-Myers Squibb Company today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
The Prime Minister today set out responsible, fair, and necessary plans to tackle the Covid backlogs, reform adult social care, and bring the health and social care system closer together on a long term, sustainable footing.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.
› Verified 8 days ago
St John Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3530 Long Beach Blvd Ste 120, Long Beach, CA 90807 Phone: 562-989-1200 | |
Bao Quoc Le Md. Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2944 E Anaheim St, Long Beach, CA 90804 Phone: 562-599-5777 Fax: 562-433-2886 | |
Salida Del Sol Ecm Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5350 Atlantic Ave, Long Beach, CA 90805 Phone: 562-269-4355 | |
Prohealth Partners, A Medical Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 911 E San Antonio Dr, Suite 6, Long Beach, CA 90807 Phone: 562-423-6441 Fax: 562-422-1301 | |
Ahf Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3500 E Pacific Coast Hwy, Long Beach, CA 90804 Phone: 323-436-5019 Fax: 323-337-9142 | |
Housecall Doctors Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3800 Kilroy Airport Way Ste 270, Long Beach, CA 90806 Phone: 949-366-1053 Fax: 949-916-0387 | |
St. Mary's Pain Management Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1040 Elm Ave Ste 100, Long Beach, CA 90813 Phone: 562-491-2145 Fax: 562-491-0153 |